Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 12 January 2016 | By Michael Mezher
In 2015, the European Medicines Agency (EMA) maintained its momentum from 2014, granting 93 positive opinions, 39 of which were for new active substances. The agency also recommended 18 orphan drugs for approval, breaking last year's record of 17.
Notably, EMA trailed just behind the US Food and Drug Administration (FDA)'s Center for Drug Evaluation and Research (CDER) for the year. In 2015, CDER approved 45 new drugs, 21 of which had been granted orphan drug designation by the agency.
While the EU is still slightly behind the US in terms of orphan drug approvals, it has closed the gap significantly in the 16 years since it established incentives for orphan drugs under its orphan regulation, known as Regulation (EC) No 141/2000.
One major difference between the two regulators is the number of drugs that benefited from an expedited review. In 2015, EMA recommended five drugs for approval under its accelerated assessment procedure, which reduces the assessment period for a drug from 210 days to 150. However, in 2015, FDA approved 27 drugs using one or more of the agency's four types of expedited review: fast track, breakthrough, priority review and accelerated approval.
In 2015, EMA recommended three drugs for conditional marketing authorization, Blincyto, Tagrisso and Zykadia. In the EU, a conditional marketing authorization is granted to drugs that fill an unmet need and treat rare or life-threatening diseases using less clinical data than would typically be required, under the condition that the sponsor will complete certain post-authorization study requirements.
EMA also recommended authorization for three drugs, Obizur, Raxone and Strensiq "under exceptional circumstances." This type of authorization allows patients to access drugs for conditions that are too rare to study in a traditional manner, or would be unethical to study. Similar to conditional marketing authorization, drugs authorized under exceptional circumstances generally must follow "specific post-authorization obligations."
EMA Human Medicines Highlights 2015
Tags: New active substance, new chemical entity, 2015 approvals, Marketing authorization
Regulatory Focus newsletters
All the biggest regulatory news and happenings.